The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

This systematic review evaluates the clinical outcomes and molecular predictors of response
to pembrolizumab in patients with advanced and metastatic cervical cancer. We adhered to …

Immunotherapy represented by anti-PD-(L) 1 and anti-CTLA-4 inhibitors has revolutionized
cancer treatment, but challenges related to resistance and toxicity still remain. Due to the …

Despite the introduction of targeted vaccines and screening protocols, locally advanced
cervical cancer represents a median proportion of 37% among all cervical carcinomas …

Background Radiotherapy plus concurrent chemotherapy is a standard method for treating
locally advanced cervical cancer (LACC). Immune checkpoint inhibitors (ICIs) are widely …

Cervical cancer (CC) remains a prevalent malignancy and a significant global public health
concern, primarily driven by persistent human papillomavirus (HPV) infections. The …

This study investigated the efficacy and safety of toripalimab in combination with concurrent
platinum‐based chemoradiation in patients with untreated locally advanced cervical cancer …

Abstract Purpose This phase I/II trial (ChiCTR2000032879) assessed the safety and efficacy
of toripalimab combined with chemoradiotherapy for locally advanced cervical squamous …

Background The prognostic significance of Treg and Th17 cells, as well as their ratio
(Th17/Treg), in cervical cancer remains a topic of debate. Our study aimed to clarify their …

Introduction Cervical cancer remains one of the most common gynecologic malignancies
worldwide. A disproportionate burden of cases occurs in developing countries due to …